In today’s briefing:
- Quiddity Leaderboard ChiNext & ChiNext 50 Jun 24: US$313mn One-Way, Four Names with Double-Impacts
- Amgen Inc: An Analysis Of The Pipeline Progress and Development! – Major Drivers
- Pre-IPO Cloudbreak Pharma – The Business, the Concerns and the Outlook
- IDEXX Laboratories: Growing Global Direct Commercial Capability & Other Major Drivers
Quiddity Leaderboard ChiNext & ChiNext 50 Jun 24: US$313mn One-Way, Four Names with Double-Impacts
- The ChiNext Index represents the performance of the 100 largest and most liquid A-share stocks listed on the ChiNext Market of the Shenzhen Stock Exchange.
- The ChiNext 50 index is a subset of the ChiNext Index and it consists of the top 50 names in the ChiNext index with the highest daily average turnover.
- In this insight, we take a look at the names leading the race to become ADDs and DELs in the June 2024 index rebal event.
Amgen Inc: An Analysis Of The Pipeline Progress and Development! – Major Drivers
- Amgen’s Fourth Quarter 2023 Financial Results Conference Call highlighted several strategic moves and positive outcomes for the biotechnology company.
- This past year, the company acquired Horizon Therapeutics, which foundationalized a new branch contributing to its growth.
- Also, 18 of Amgen’s medicines reached record annual sales, including Repatha, Prolia, EVENITY, TEZSPIRE, BLINCYTO, KRYSTEXXA, and UPLIZNA. Baptista Research looks to evaluate the different factors that could influence the company’s price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.
Pre-IPO Cloudbreak Pharma – The Business, the Concerns and the Outlook
- Surgery is doctors’ first choice in many cases. Ophthalmic medical devices are also popular. Compared to the market size of ophthalmic surgeries/medical devices, market size of ophthalmic drugs is small.
- Although CLOUDBREAK’s pipeline has the potential to become first-in-class/best-in-class therapies to address unmet medical needs, considering fierce competition, the real market opportunities for its drug candidates may be smaller-than-expected
- In last funding round before the IPO, CLOUDBREAK was valued at US$469 million.Valuation of CLOUDBREAK should be lower than Ocumension Therapeutics. So, premium space for IPO pricing may be limited.
IDEXX Laboratories: Growing Global Direct Commercial Capability & Other Major Drivers
- In 2023, IDEXX Laboratories posted strong quarterly and annual results.
- The company reported an 8% organic revenue increase in Q4, largely driven by gains in CAG Diagnostic recurring revenues.
- Operating profits also rose 8% as reported, with a 10% increase on a comparable basis, aided by robust gross margin gains and OpEx leverage.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
